UMD IBBR - 9600 Gudelsky Drive, Rockville, MD 20850

February 28, 2019

Unique opportunity to meet 1:1 with multiple SBIR program managers and experts.


8:00 a.m. - 8:30 a.m. – Networking and Registration

8:30 a.m. - 12:00 p.m. – Program Overviews. Agencies represented:

NSF (National Science Foundation)

NIH NIA (National Institute on Aging)

NIH NCI (National Cancer Institute)

NIH NHLBI (National Heart, Lung, and Blood Institute)

NIH NIDA (National Institute on Drug Abuse)

US Army (invited)

12:00 p.m. - 1:00 p.m. – Networking Lunch

1:00 p.m. – 1:30 p.m. – Writing Specific Aims Page

1:30 – 2 p.m. – Writing Your Phase II Commercialization Program

2:00 – 2:30 p.m.  – Q&A with All speakers

2:30 - 4:00 p.m. - 1:1 – Meetings with Program Managers*

Pre-Registration REQUIRED: RSVP by noon, February 26 at

No charge for entrepreneurs to attend • If seeking 1:1 meeting(s) please include organization(s) in RSVP.

*You do not have to participate in 1:1 meetings. However, to do so, you must attend the overview session in person. 


GetWellNetwork, the Precision Engagement health care company reaching 10 million patients annually, announced today a pivotal 2018 which will propel the company into 2019 as it continues to lead the evolution of patient engagement. The company furthered global expansion efforts, made several executive hires and acquired leading digital health company HealthLoop to catalyze growth in the ambulatory space.


Lung cancer may not be the first thought that crosses the mind when talking about breathalyzer tests. But, what if lung cancer detection were as easy as breathing into a device? That is the goal of a group of researchers from the University of Exeter who have recently taken a new approach to e-nose technology integrated with multi-layered graphene for early detection of lung cancer.

Digital Health 100 LOGO 2018

Explore the 2018 Global Digital Health 100.

The Global Digital Health 100 is one of the HealthTech industries foremost technology awards programmes, celebrating innovation and entrepreneurship. It recognises and supports health technology companies that are demonstrating the greatest potential to change the way that healthcare is delivered.


Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 15/683,408, “Fluorocyclopentenylcytosine Methods of Use.” The patent application covers the use of RX-3117 in a broad range of tumor types that over-express UCK2, the enzyme that activates RX-3117. The company expects the patent to be issued within a few months from the notice of allowance and provide protection to 2036. 

biotalk finkel article image

Dr. Julia Finkel, Pediatric Anesthesiologist, Children's National Medical Center, joins Biotalk host Rich Bendis to discuss pain care management, the founding of startup AlgometRx, and the funding of this new companyDr. Julia Finkel, Pediatric Anesthesiologist, Children's National Medical Center, joins Biotalk host Rich Bendis to discuss pain care management, the founding of startup AlgometRx, and the funding of this new company.

Julia Finkel, M.D., is a pediatric anesthesiologist and director Pain Medicine Research and Development in the Sheikh Zayed Institute for Pediatric Surgical Innovation.

Dr. Finkel has extensive experience designing and conducting clinical trials relating to analgesics in children and has received both industry and federal funding of her research. Dr. Finkel is regularly invited to speak at national meetings on topics related to pediatric pain management.

Listen now on iTunes Google Play , and TuneIn


The extremely active lab real estate market is a bell-weather for the upcoming hyper-competitive talent market. Based on the recent real estate transactions and related hiring forecasts, we estimate the range of new positions in the Maryland life sciences market to be between 1,150 to 2,300 new hires in 2019.


In the last decade, crowdfunding has become a popular way to finance all sorts of projects and products. Biotech is no exception, but many question whether the high risk and long term nature of investing in the biotech industry makes it a good fit for equity crowdfunding.


Maryland Tech Council (MTC) announced today that the Montgomery County Economic Development Corporation (MCEDC) will continue its partnership with and support of MTC's Venture Mentoring Services (VMS) program. MCEDC has funded the mentoring program for three years and will continue to support it in 2019-to further augment the growth of Montgomery County's target industries-technology and life sciences, while providing a key component to sustain economic growth in the County.


Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments in rare and orphan diseases in pediatrics and neurology, announced today that it has moved its U.S. Corporate Offices to 540 Gaither Road Suite 400 located in Rockville, Maryland. The company had previously been based in Baltimore, Maryland.


The highly touted gene-editing technology CRISPR is facing one of its first real-world tests. As many as 12 patients who live with the blood disorders sickle cell anemia or beta-thalassemia have started enrolling in a Europe-based clinical trial that may serve as an early indicator of whether gene editing will live up to the hype.


You thought the Shark Tank was tough…
Wait until you enter the the BioHealth Capital Region Crab Trap!

Submit your application for the opportunity to present your innovation and be named the region’s early stage biohealth company with the most commercial potential at the 2019 BioHealth Regional Forum, $10,000, and MORE!

Application Deadline: March 1, 2019

Finalists will be announced: March 21st, 2019

Finalist Presentations BioHealth Capital Region Forum event: April 9th, 2019

Submit Application »


The partners at SR One, a storied corporate biotech VC with investments across a wide range of drug developers on both sides of the Atlantic, are engaged in talks to split away from the pharma giant GlaxoSmithKline, according to sources familiar with a move that’s been in the works since at least late last year.

bhi sbir logo

HOLD THE DATE – February 28, 2019  8 am. – 3:00 p.m.

Meet 1:1 with SBIR program managers. Learn more about their funding programs (SBIR and more!) 

8-8:30 Networking and Registration

8:30 – 12:00 p.m. – Program Overviews

12:00 p.m. – 1:00 p.m. – Networking Lunch

1:00 p.m. – 3:00 p.m – 1:1 Meetings with Program Managers*

Agencies represented include:   

*The program overview will be available by videoconference.

**You do not have to participate in 1:1 meetings.  However, to do so, you must attend the overview session in person.
PRE-REGISTRATION IS REQUIRED:  RSVP by noon 2/26:  This email address is being protected from spambots. You need JavaScript enabled to view it.


After weeks of speculation that biopharma deal making would cool off, 2019 got off to a flying start as far as mergers-and-acquisitions (M&A) is concerned, thanks to two blockbuster transactions: Bristol-Myers Squibb’s planned $74 billion acquisition of Celgene, followed four days later by Eli Lilly’s planned $8 billion purchase of Loxo Oncology—a deal that quickly became the buzz of the J.P. Morgan 37th Healthcare Conference, held earlier this month in San Francisco.


Our National Cancer Institute-University of Maryland (NCI-UMD) Partnership for Integrative Cancer Research reflects the broad interests of our participating NCI and UMD researchers. We are delighted to invite you to our annual NCI-UMD Partnership for Integrative Cancer Research Symposium on Friday, February 8th from 10am-4pm which will take place in Bethesda, Maryland in the John Edward Porter Neuroscience Research Center at the National Institutes of Health, Bldg 35A, Room 620/630. Please register and plan to participate in our October symposium. The final agenda will be announced shortly.


The past decade has seen intensified research collaboration between pharmaceutical companies and academic institutions. Although such partnerships are recognized as a source of innovation and a key pillar to advance science in drug discovery, they are replete with challenges. Despite much anecdotal evidence and debate, fact-based evidence on the nature of these challenges and how to manage them is scarce.


Deloitte has surpassed its peers to become the world's most valuable professional services brand, according to the 2019 Global 500 report issued by Brand Finance on 22 January 2019. Deloitte's strong performance was due to higher scores in Brand Finance's metrics of familiarity, consideration, satisfaction, preference, recommendation and revenue.   


2019 has kicked off with a wave of innovative health care solutions highlighted at mega-conferences like CES and the J.P. Morgan Healthcare Conference - from the introduction of the first wearable blood pressure monitor to virtual home health care for seniors to online vision tests allowing patients to renew prescriptions from anywhere at anytime. We are truly living through an age of disruption spurred by technological advances.


United Therapeutics Corporation (Nasdaq: UTHR) today announced the closing of the transactions contemplated by its license agreement with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA). Under the agreement, United Therapeutics acquired exclusive, worldwide rights to develop and manufacture the Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH).  Upon closing, United Therapeutics paid Arena $800 million. Arena is also entitled to potential milestone payments of up to $400 million based on the achievement of certain regulatory events as well as low double-digit tiered royalties on annual net sales of ralinepag products.